Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9508-9508 ◽  
Author(s):  
Robert Hans Ingemar Andtbacka ◽  
Reinhard Dummer ◽  
David E. Gyorki ◽  
Adam C. Berger ◽  
Robert Martin Conry ◽  
...  
Keyword(s):  
Interim Analysis ◽  
Neoadjuvant Treatment ◽  
Stage Iiib ◽  
Phase 2 ◽  
Talimogene Laherparepvec ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

2021 ◽  
Vol 27 (10) ◽  
pp. 1789-1796
Author(s):  
R. Dummer ◽  
D. E. Gyorki ◽  
J. Hyngstrom ◽  
A. C. Berger ◽  
R. Conry ◽  
...  
Keyword(s):  
Stage Iiib ◽  
Phase 2 ◽  
Talimogene Laherparepvec ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

2011 ◽  
Vol 17 (21) ◽  
pp. 6905-6913 ◽  
Author(s):  
Richard S. Finn ◽  
Carmelo Bengala ◽  
Nuhad Ibrahim ◽  
Henri Roché ◽  
Joseph Sparano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Single Agent ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document